Drug details

Arcapta Neohaler (indacaterol inhalation powder)

type of

Arcapta Neohaler (indacaterol) Inhalation Powder is a selective beta2-adrenergic agonist indicated for long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Arcapta Neohaler is not indicated for the treatment of asthma and increases the risk of asthma-related death.

The drug is often used to treat Asthma , Chronic obstructive pulmonary disease .

The following drugs are related to Arcapta Neohaler, either as a replacement or used together:

• Advair Diskus (fluticasone propionate)
• Advair HFA (fluticasone propionate and salmeterol)
• VoSpire ER (albuterol sulfate extended-release tablets)
• Ventolin HFA (albuterol sulfate inhalation aerosol)
• Ventolin Solution (albuterol sulfate inhalation solution)
• Ventolin Syrup (albuterol sulfate syrup)
• Qvar (beclomethasone dipropionate hfa)
• Bevespi Aerosphere (glycopyrrolate and formoterol fumarate inhalation aerosol)
• Symbicort Aerosphere (budesonide and formoterol fumarate inhalation aerosol)
• Lufyllin (dyphylline)
• Flovent (fluticasone propionate)
• Flovent Diskus (fluticasone propionate)
• Flovent HFA (fluticasone propionate hfa)
• Utibron Neohaler (indacaterol and glycopyrrolate inhalation powder, for oral inhalation use)
• Yupelri (revefenacin inhalation solution)
• Stiolto Respimat (tiotropium bromide and olodaterol)